LRRC15 Rabbit antibody Ab Aff - Purified
- Known as:
- LRRC15 Rabbit (anti-) Antibody Aff - Purified
- Catalog number:
- GTX120895
- Product Quantity:
- 0.1 ml
- Category:
- -
- Supplier:
- ACR
- Gene target:
- LRRC15 Rabbit antibody Aff - Purified
Related genes to: LRRC15 Rabbit antibody Ab Aff - Purified
- Gene:
- LRRC15 NIH gene
- Name:
- leucine rich repeat containing 15
- Previous symbol:
- -
- Synonyms:
- LIB
- Chromosome:
- 3q29
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-25
- Date modifiied:
- 2015-08-27
Related products to: LRRC15 Rabbit antibody Ab Aff - Purified
Related articles to: LRRC15 Rabbit antibody Ab Aff - Purified
- Leucine-rich repeat-containing 15 (LRRC15) is a membrane protein whose overexpression has been linked to poorer survival outcomes in various malignant neoplasms. However, its role in distal extrahepatic bile duct carcinoma (DBDC) remains unclear. LRRC15 protein expression in tumor cells and stroma was evaluated with 196 surgically resected DBDCs, and compared with clinicopathological variables, including patients' overall survival (OS) and recurrence-free survival (RFS). LRRC15 protein expression was identified in stroma of 21 DBDCs (11%) and tumor cells in 67 cases (34%). On the basis of the combined expression patterns of LRRC15, DBDCs were classified into 4 groups: LRRC15 cancer+/stroma- (25%), cancer-/stroma+ (2%), cancer+/stroma+ (9%), and cancer-/stroma- (64%). The stromal LRRC15+ group exhibited more frequent pancreatic invasion compared with the stromal LRRC15- group (P=0.004*). The LRRC15 cancer+/stroma+ group showed the most frequent pancreas invasion (P=0.016*). The patients with stromal LRRC15+ group had significantly worse OS (5-year survival rate, 15.4% vs. 31.6%; P=0.013*) and RFS (19.1% vs. 38.9%; P=0.005*) compared with those in the stromal LRRC15- DBDCs. Stromal LRRC15 expression was significantly associated with poor prognosis and showed a strong trend toward being an independent prognostic factor for both OS (P=0.051) and RFS (P=0.061). Patients with DBDCs in the LRRC15 cancer+/stroma+ group had the worst RFS (P=0.010*) and OS (P=0.008*) by univariate analysis. LRRC15 overexpression was observed in a subset of DBDCs and was associated with pancreatic invasion and worse OS and RFS. Consequently, LRRC15 expression can be used as an indicator of poor survival in patients with DBDCs, particularly when both cancer cells and stromal expression are present. - Source: PubMed
Publication date: 2026/07/15
Chun JihyunJung Deok-BeomShin JinhoJeong HyehyunYoo ChanghoonMyung Seung-JaeHong Seung-Mo - As the principal ECM-producing cell type, fibroblasts are essential regulators of tissue architecture and function in development, homeostasis, and disease. While their disease-promoting functions in fibrosis have long been the center of attention, it is increasingly recognized that fibroblasts exert critical homeostatic roles across organs, acting as sentinels that regulate the function, proliferation, and recruitment of epithelial, endothelial and immune cells in health and disease. Here, we will review the roles of fibroblasts and fibroblast-like cells in tissue maintenance, physiological wound healing, regeneration, maladaptive fibrosis, and cancer across major organs, including the skin, lung, liver, intestine, and kidney, and highlight organ-specific and shared populations and functions. We will discuss the role of PI16+ and COL15A1+ universal fibroblasts, organ-specific fibroblasts, and pericyte and pericyte-like stellate cells as cellular sources for the majority of CTHRC1+ activated fibroblasts and αSMA+ or LRRC15+ myofibroblasts and highlight the functions of specialized subpopulations, such as inflammatory fibroblasts, antigen-presenting fibroblasts, and fibroblast-like cells, including mesothelial and smooth muscle cells. A refined understanding of fibroblast heterogeneity holds promise for novel therapeutic concepts, aimed at targeting pathogenic subpopulations while preserving or enhancing homeostatic functions. - Source: PubMed
Publication date: 2026/07/08
Yang XiaochunSteffani MarcellaNadella SandeepSheppard DeanRieder FlorianRinkevich YuvalKramann RafaelTuveson David ASchwabe Robert F - Targeting stromal cells such as inflammatory fibroblasts presents a potential avenue to alleviate autoimmune inflammation and fibrosis. This study aimed to characterize LRRC15 expression in rheumatoid arthritis (RA) and systemic sclerosis (SSc) across fibroblast subsets and assess whether targeting LRRC15-expressing fibroblasts can be beneficial for the treatment of fibrosis and fibroblast-mediated inflammation. - Source: PubMed
Tu XintaoBach Thao-NguyenBaghela ArjunZielstorff MarkSmallridge WilliamChen QianMotlagh SohaBarr TravisSze Marc AlexanderJang In SockZhang-Hoover JieTamburino Alex MPeterson Vanessa MKamath Rajesh VLevesque Marc CVroom KarinMalhotra Nidhi - Osteosarcoma (OTS) is a highly aggressive primary bone malignancy characterized by profound genomic instability and a complex, immunosuppressive tumor immune microenvironment (TIME). Despite the established standard of neoadjuvant chemotherapy and surgical resection, the 5-year overall survival rates for metastatic or relapsed disease have remained stagnant at approximately 40% for decades. The high degree of heterogeneity and the "immune cold" nature of OTS pose significant challenges to the efficacy of conventional and emerging therapies. This review aims to summarize recent advances in the genomic and immunological landscape of OTS to inform personalized precision medicine. - Source: PubMed
Publication date: 2026/06/10
Yang ChenchenYu YiyangWang YaqiCai ZhenyuZhao YuweiMa HengyueXu JieZhu HuaiqiuRen TingtingTang XiaodongXie Lu - Leucine-rich-repeat-containing protein 15 (LRRC15) is selectively expressed on cancer-associated fibroblasts (CAFs) and constitutes a promising biomarker for imaging the tumor microenvironment. Using a combinatorial library approach, assisted by machine learning, we developed disulfide-constrained peptides (DCPs), notably ML-YSD-07 and ML-PD-03, that demonstrate subnanomolar affinities for murine LRRC15 (muLRRC15) and specifically localize onto muLRRC15-expressing fibroblasts. PET imaging with F-radiolabeled ML-YSD-07 exhibits specific tumor accumulation in a murine pancreatic cancer model highly enriched with LRRC15-expressing CAFs. Crystal structures of apo-muLRRC15 and of ML-YSD-07-bound muLRRC15 show that the DCPs evolved to adopt a distinct binding conformation that efficiently interacts with a flat epitope on muLRRC15. Collectively, this work identifies potent, molecularly engineered LRRC15-binding peptides and further highlights LRRC15 as a valuable CAF biomarker for cancer imaging applications. - Source: PubMed
Publication date: 2026/06/05
Tombling Benjamin JCai FeiWendorff Timothy JOgasawara AnnieGill Herman STinianow Jeff NChang AndrewBalana Aaron TPeng LinglingMiller Stephen EWalters Benjamin TLictao AaronYu QinyingDeWitt David CWei YuehuaWu Sunny ZSudhamsu JawaharKrishnamurty Akshay TWilliams Simon PMarik JanZhang YingnanMaun Henry RKirchhofer Daniel